[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:dmd-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"DMD Gene",11,9,[8,16,23,29,36,42,49,56,62,68,75],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07160634","A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)",[12],"Phase 3","RECRUITING","2026-08-26T02:16:38.053590Z","2026-06-04T01:30:07.901496Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07429240","PBGENE-DMD Phase 1\u002F2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)",[20],"Phase 1\u002FPhase 2","2026-08-26T02:16:34.792807Z","2026-05-13T02:55:06.704813Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06138639","A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)",[20],"2026-08-26T02:18:15.214990Z","2026-05-05T02:43:28.676613Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06692426","Trial of Cell Based Therapy for DMD",[33],"Phase 1","2026-08-26T02:18:57.189473Z","2026-05-05T02:43:28.180268Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT04906460","Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)",[20],"2026-08-26T02:19:27.519777Z","2026-05-05T02:43:28.128996Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":47,"content_modified":48},"NCT05412394","Once Weekly Infant Corticosteroid Trial for DMD",[46],"Phase 4","2026-08-26T02:19:19.975067Z","2026-05-05T02:43:26.676741Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":54,"content_modified":55},"NCT05996003","NS-089\u002FNCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)",[53],"Phase 2","2026-08-26T02:18:46.948970Z","2026-05-05T02:35:31.916688Z",{"nct_id":57,"title":58,"phases":59,"status":13,"updated_at":60,"content_modified":61},"NCT06817382","A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)",[33],"2026-08-26T02:17:57.117858Z","2026-05-05T02:35:31.904026Z",{"nct_id":63,"title":64,"phases":65,"status":13,"updated_at":66,"content_modified":67},"NCT07092540","The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy",[],"2026-08-26T02:17:15.156099Z","2026-05-13T02:55:06.653457Z",{"nct_id":69,"title":70,"phases":71,"status":72,"updated_at":73,"content_modified":74},"NCT07642635","Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy",[20],"NOT_YET_RECRUITING","2026-08-26T02:15:20.225313Z","2026-06-14T18:39:22.260654Z",{"nct_id":76,"title":77,"phases":78,"status":79,"updated_at":21,"content_modified":80},"NCT06606340","A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice",[],"ENROLLING_BY_INVITATION","2026-06-16T05:54:07.762469Z"]